Madison Explorations, Inc. Announces the Development Progress of Specific Cannabinoid Separation

The Company believes that using the CannaStrips technology to deliver patient therapy of cannabinoids that are believed to have antioxidant properties unrelated to NMDA receptor antagonism can improve the effectiveness. There are a number of specific cannabinoids contained in marijuana, these cannabinoids have been found useful in the treatment and prophylaxis of a wide variety of oxidation associated diseases, such as ischemic, age-related disorders and inflammatory symptoms as well as cataracts, sleep disorders, seizures and autoimmune diseases. The cannabinoids are believed to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic invectives, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. The ability to separate the cannabinoids from the psychoactive THC will allow therapy free of the effects of THC, this is particularly advantageous in therapies involving children because they avoid toxicity that is encountered with therapies involving psychoactive high dose THC cannabinoids, specifically consisting of H, CH₃, and COCH₃.

The CEO of Madison Explorations, Inc. Brent Inzer commented: "The ability to deliver cannabinoid therapy specific to a patients exact needs greatly increases the possibility for monitoring the effectiveness of the therapy and hopefully promoting clinical trails and further in depth cannabinoid studies and testing."

Brent Inzer, CEO, Madison Explorations

About Madison Exploration Inc.: The Company is a technology company positioned to become the leading smokeless cannabinoid technology provider, establishing a strong reputation for the highest quality, dosage reliability and formulation innovation. The Company is continuing its development and improvement of the products, production methods and formulations for its proprietary technology "CannaStrips" and is in advanced development of a number of additional smokeless delivery systems designed specifically for smokeless cannabinoid therapy.

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that Madison Explorations, Inc. expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in Madison Explorations, Inc.'s Quarterly and Annual Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of Madison Explorations, Inc.'s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Madison Explorations, Inc.'s forward-looking statements. Except as required by law, Madison Explorations, Inc. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Madison Explorations, Inc. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.